166 related articles for article (PubMed ID: 23689213)
1. Advancing the science of pharmacovigilance.
Honig PK
Clin Pharmacol Ther; 2013 Jun; 93(6):474-5. PubMed ID: 23689213
[TBL] [Abstract][Full Text] [Related]
2. On the evidence consistency of pharmacovigilance outcomes between Food and Drug Administration Adverse Event Reporting System and electronic medical record data for acute mania patients.
Duan R; Zhang X; Du J; Huang J; Tao C; Chen Y
Health Informatics J; 2020 Jun; 26(2):753-764. PubMed ID: 30887861
[TBL] [Abstract][Full Text] [Related]
3. Logistic regression in signal detection: another piece added to the puzzle.
Caster O; Norén GN; Madigan D; Bate A
Clin Pharmacol Ther; 2013 Sep; 94(3):312. PubMed ID: 23695184
[No Abstract] [Full Text] [Related]
4. Response to "Logistic regression in signal detection: another piece added to the puzzle".
Harpaz R; DuMouchel W; LePendu P; Bauer-Mehren A; Ryan P; Shah NH
Clin Pharmacol Ther; 2013 Sep; 94(3):313. PubMed ID: 23756371
[No Abstract] [Full Text] [Related]
5. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?
Coloma PM; Trifirò G; Patadia V; Sturkenboom M
Drug Saf; 2013 Mar; 36(3):183-97. PubMed ID: 23377696
[TBL] [Abstract][Full Text] [Related]
7. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
8. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.
Harpaz R; DuMouchel W; LePendu P; Bauer-Mehren A; Ryan P; Shah NH
Clin Pharmacol Ther; 2013 Jun; 93(6):539-46. PubMed ID: 23571771
[TBL] [Abstract][Full Text] [Related]
9. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
Cederholm S; Hill G; Asiimwe A; Bate A; Bhayat F; Persson Brobert G; Bergvall T; Ansell D; Star K; Norén GN
Drug Saf; 2015 Jan; 38(1):87-100. PubMed ID: 25539877
[TBL] [Abstract][Full Text] [Related]
10. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity.
Maro JC; Brown JS; Dal Pan GJ; Kulldorff M
Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):839-48. PubMed ID: 24700557
[TBL] [Abstract][Full Text] [Related]
11. Standard-based comprehensive detection of adverse drug reaction signals from nursing statements and laboratory results in electronic health records.
Lee S; Choi J; Kim HS; Kim GJ; Lee KH; Park CH; Han J; Yoon D; Park MY; Park RW; Kang HR; Kim JH
J Am Med Inform Assoc; 2017 Jul; 24(4):697-708. PubMed ID: 28087585
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of Spontaneously Reported Adverse Events].
Nakamura M
Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
[TBL] [Abstract][Full Text] [Related]
13. Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics.
Tilson HH; Madre LK; Califf RM
Clin Pharmacol Ther; 2007 Aug; 82(2):118-21. PubMed ID: 17632533
[TBL] [Abstract][Full Text] [Related]
14. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
Xia HA; Ma H; Carlin BP
J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
[TBL] [Abstract][Full Text] [Related]
15. Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.
Florek AG; Nardone B; Thareja S; Tran G; Giles FJ; West DP
Br J Dermatol; 2017 Nov; 177(5):e220-e221. PubMed ID: 28646575
[No Abstract] [Full Text] [Related]
16. Detection of adverse drug reaction signals using an electronic health records database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) algorithm.
Yoon D; Park MY; Choi NK; Park BJ; Kim JH; Park RW
Clin Pharmacol Ther; 2012 Mar; 91(3):467-74. PubMed ID: 22237257
[TBL] [Abstract][Full Text] [Related]
17. From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources.
Trifirò G; Sultana J; Bate A
Drug Saf; 2018 Feb; 41(2):143-149. PubMed ID: 28840504
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.
Awada Z; Zgheib NK
Pharmacogenomics; 2014 Apr; 15(6):845-56. PubMed ID: 24897290
[TBL] [Abstract][Full Text] [Related]
19. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
20. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
